ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis

Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. With the use of microarrays, the gene expression pr...

Full description

Saved in:
Bibliographic Details
Published in:Analytical cellular pathology (Amsterdam) Vol. 28; no. 5-6; pp. 259 - 272
Main Authors: Lind, Guro E, Kleivi, Kristine, Meling, Gunn I, Teixeira, Manuel R, Thiis-Evensen, Espen, Rognum, Torleiv O, Lothe, Ragnhild A
Format: Journal Article
Language:English
Published: Netherlands IOS Press 2006
Hindawi Limited
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. With the use of microarrays, the gene expression profiles of colon cancer cell lines before and after treatment with the demethylating agent 5-aza-2'-deoxycytidine were identified and compared. The expression of the responding genes was compared with microarray expression data of primary colorectal carcinomas. Four of these down-regulated genes were subjected to methylation-specific PCR, bisulphite sequencing, and quantitative gene expression analysis using tumors (n=198), normal tissues (n=44), and cell lines (n=30). Twenty-one genes with a CpG island in their promoter responded to treatment in cell lines, and were simultaneously down-regulated in primary colorectal carcinomas. Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). For the latter two genes, hypermethylation was significantly associated with absence or reduced gene expression. The methylation status of ADAMTS1, CRABP1, and NR3C1 was further investigated in 116 colorectal carcinomas and adenomas. Twenty-three of 63 (37%), 7/60 (12%), and 2/63 (3%) adenomas, as well as 37/52 (71%), 25/51 (49%), and 13/51 (25%) carcinomas were hypermethylated for the respective genes. These genes were unmethylated in tumors (n=82) from three other organs, prostate, testis, and kidney. Finally, analysis of normal colorectal mucosa demonstrated that the observed promoter hypermethylation was cancer-specific. By using a refined microarray screening approach we present three genes with cancer-specific hypermethylation in colorectal tumors, ADAMTS1, CRABP1, and NR3C1.
AbstractList Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. With the use of microarrays, the gene expression profiles of colon cancer cell lines before and after treatment with the demethylating agent 5-aza-2'-deoxycytidine were identified and compared. The expression of the responding genes was compared with microarray expression data of primary colorectal carcinomas. Four of these down-regulated genes were subjected to methylation-specific PCR, bisulphite sequencing, and quantitative gene expression analysis using tumors (n=198), normal tissues (n=44), and cell lines (n=30). Twenty-one genes with a CpG island in their promoter responded to treatment in cell lines, and were simultaneously down-regulated in primary colorectal carcinomas. Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). For the latter two genes, hypermethylation was significantly associated with absence or reduced gene expression. The methylation status of ADAMTS1, CRABP1, and NR3C1 was further investigated in 116 colorectal carcinomas and adenomas. Twenty-three of 63 (37%), 7/60 (12%), and 2/63 (3%) adenomas, as well as 37/52 (71%), 25/51 (49%), and 13/51 (25%) carcinomas were hypermethylated for the respective genes. These genes were unmethylated in tumors (n=82) from three other organs, prostate, testis, and kidney. Finally, analysis of normal colorectal mucosa demonstrated that the observed promoter hypermethylation was cancer-specific. By using a refined microarray screening approach we present three genes with cancer-specific hypermethylation in colorectal tumors, ADAMTS1, CRABP1, and NR3C1.
Background: Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. Methods: With the use of microarrays, the gene expression profiles of colon cancer cell lines before and after treatment with the demethylating agent 5-aza-2′-deoxycytidine were identified and compared. The expression of the responding genes was compared with microarray expression data of primary colorectal carcinomas. Four of these down-regulated genes were subjected to methylation-specific PCR, bisulphite sequencing, and quantitative gene expression analysis using tumors (n=198), normal tissues (n=44), and cell lines (n=30). Results: Twenty-one genes with a CpG island in their promoter responded to treatment in cell lines, and were simultaneously down-regulated in primary colorectal carcinomas. Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). For the latter two genes, hypermethylation was significantly associated with absence or reduced gene expression. The methylation status of ADAMTS1, CRABP1, and NR3C1 was further investigated in 116 colorectal carcinomas and adenomas. Twenty-three of 63 (37%), 7/60 (12%), and 2/63 (3%) adenomas, as well as 37/52 (71%), 25/51 (49%), and 13/51 (25%) carcinomas were hypermethylated for the respective genes. These genes were unmethylated in tumors (n=82) from three other organs, prostate, testis, and kidney. Finally, analysis of normal colorectal mucosa demonstrated that the observed promoter hypermethylation was cancer-specific. Conclusion: By using a refined microarray screening approach we present three genes with cancer-specific hypermethylation in colorectal tumors, ADAMTS1, CRABP1, and NR3C1.
Background : Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. Methods : With the use of microarrays, the gene expression profiles of colon cancer cell lines before and after treatment with the demethylating agent 5-aza-2′-deoxycytidine were identified and compared. The expression of the responding genes was compared with microarray expression data of primary colorectal carcinomas. Four of these down-regulated genes were subjected to methylation-specific PCR, bisulphite sequencing, and quantitative gene expression analysis using tumors ( n =198), normal tissues ( n =44), and cell lines ( n =30). Results : Twenty-one genes with a CpG island in their promoter responded to treatment in cell lines, and were simultaneously down-regulated in primary colorectal carcinomas. Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). For the latter two genes, hypermethylation was significantly associated with absence or reduced gene expression. The methylation status of ADAMTS1, CRABP1, and NR3C1 was further investigated in 116 colorectal carcinomas and adenomas. Twenty-three of 63 (37%), 7/60 (12%), and 2/63 (3%) adenomas, as well as 37/52 (71%), 25/51 (49%), and 13/51 (25%) carcinomas were hypermethylated for the respective genes. These genes were unmethylated in tumors ( n =82) from three other organs, prostate, testis, and kidney. Finally, analysis of normal colorectal mucosa demonstrated that the observed promoter hypermethylation was cancer-specific. Conclusion : By using a refined microarray screening approach we present three genes with cancer-specific hypermethylation in colorectal tumors, ADAMTS1, CRABP1 , and NR3C1 .
BACKGROUNDGene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel target genes inactivated through promoter hypermethylation in colorectal tumor development. METHODSWith the use of microarrays, the gene expression profiles of colon cancer cell lines before and after treatment with the demethylating agent 5-aza-2'-deoxycytidine were identified and compared. The expression of the responding genes was compared with microarray expression data of primary colorectal carcinomas. Four of these down-regulated genes were subjected to methylation-specific PCR, bisulphite sequencing, and quantitative gene expression analysis using tumors (n=198), normal tissues (n=44), and cell lines (n=30). RESULTSTwenty-one genes with a CpG island in their promoter responded to treatment in cell lines, and were simultaneously down-regulated in primary colorectal carcinomas. Among 20 colon cancer cell lines, hypermethylation was subsequently identified for three of four analyzed genes, ADAMTS1 (85%), CRABP1 (90%), and NR3C1 (35%). For the latter two genes, hypermethylation was significantly associated with absence or reduced gene expression. The methylation status of ADAMTS1, CRABP1, and NR3C1 was further investigated in 116 colorectal carcinomas and adenomas. Twenty-three of 63 (37%), 7/60 (12%), and 2/63 (3%) adenomas, as well as 37/52 (71%), 25/51 (49%), and 13/51 (25%) carcinomas were hypermethylated for the respective genes. These genes were unmethylated in tumors (n=82) from three other organs, prostate, testis, and kidney. Finally, analysis of normal colorectal mucosa demonstrated that the observed promoter hypermethylation was cancer-specific. CONCLUSIONBy using a refined microarray screening approach we present three genes with cancer-specific hypermethylation in colorectal tumors, ADAMTS1, CRABP1, and NR3C1.
Author Teixeira, Manuel R
Thiis-Evensen, Espen
Lothe, Ragnhild A
Rognum, Torleiv O
Kleivi, Kristine
Lind, Guro E
Meling, Gunn I
AuthorAffiliation 7 Department of Molecular Biosciences University of Oslo Oslo Norway
6 Institute of Forensic Medicine Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
1 Department of Cancer Prevention Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
2 Department of Genetics Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
3 Surgical Department Faculty Division Akershus University Hospital University of Oslo Oslo Norway
4 Department of Genetics Portuguese Oncology Institute Porto Portugal
5 Medical Department Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
AuthorAffiliation_xml – name: 3 Surgical Department Faculty Division Akershus University Hospital University of Oslo Oslo Norway
– name: 6 Institute of Forensic Medicine Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
– name: 4 Department of Genetics Portuguese Oncology Institute Porto Portugal
– name: 5 Medical Department Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
– name: 1 Department of Cancer Prevention Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
– name: 7 Department of Molecular Biosciences University of Oslo Oslo Norway
– name: 2 Department of Genetics Institute for Cancer Research Rikshospitalet-Radiumhospitalet Medical Centre Oslo Norway
Author_xml – sequence: 1
  givenname: Guro E
  surname: Lind
  fullname: Lind, Guro E
  organization: Department of Cancer Prevention, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Oslo, Norway
– sequence: 2
  givenname: Kristine
  surname: Kleivi
  fullname: Kleivi, Kristine
– sequence: 3
  givenname: Gunn I
  surname: Meling
  fullname: Meling, Gunn I
– sequence: 4
  givenname: Manuel R
  surname: Teixeira
  fullname: Teixeira, Manuel R
– sequence: 5
  givenname: Espen
  surname: Thiis-Evensen
  fullname: Thiis-Evensen, Espen
– sequence: 6
  givenname: Torleiv O
  surname: Rognum
  fullname: Rognum, Torleiv O
– sequence: 7
  givenname: Ragnhild A
  surname: Lothe
  fullname: Lothe, Ragnhild A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17167179$$D View this record in MEDLINE/PubMed
BookMark eNqFks1vEzEQxS1URNPCiTvaExdYanv9tRekEApUKh8q5Wx57XFw5ayDvYvU_75OEwE9cRpp5vknv5l3go7GNAJCzwl-QwjnZxRjcdaznmPxCC0oJbiVRPEjtCBc4pYriY_RSSk3GHeUEfwEHRNJhCSyXyBYvl9-vv5OXjerq-W7b7Wa0TVfrroVaYKDcQo-gGtMaWAb1jDCFKyJ8bZxkGE9RzPV6a5fmjA2NsWUwU4mNtO8Sfn-RQnlKXrsTSzw7FBP0Y8P59erT-3l148Xq-Vla5kUU2u952zolVJeOEwJwVwNBlz15igVuLdCeAnEAFDnO6bASiyZowIGa5noTtHFnuuSudHbHDYm3-pkgr5vpLzWJlcHEbSnwIH1QvHOMgA2WGYx5w6YraieVdbbPWs7Dxtwtu4im_gA-nAyhp96nX5rJoiimFTAywMgp18zlElvQrEQoxkhzUULRZnkUvxXSHE9m-j6Kny1F9qcSsng__yGYL3Lgt5lQe-zUNUv_jXwV3s4fncH_h6wRw
CitedBy_id crossref_primary_10_1093_biolre_ioae038
crossref_primary_10_31857_S032097252102010X
crossref_primary_10_1152_ajpcell_00336_2008
crossref_primary_10_1134_S0006297921020103
crossref_primary_10_1158_0008_5472_CAN_08_4155
crossref_primary_10_9758_cpn_2022_20_4_685
crossref_primary_10_3390_nu14071528
crossref_primary_10_1007_s10585_024_10294_2
crossref_primary_10_1016_j_psychres_2021_113774
crossref_primary_10_1242_jcs_050468
crossref_primary_10_2147_OTT_S272222
crossref_primary_10_5483_BMBRep_2023_0103
crossref_primary_10_1186_s40478_023_01514_z
crossref_primary_10_1155_2021_2606213
crossref_primary_10_3390_biology13030184
crossref_primary_10_1177_10815589241242715
crossref_primary_10_1007_s11756_021_00991_8
crossref_primary_10_1002_ajhb_23876
crossref_primary_10_18632_aging_204594
ContentType Journal Article
Copyright Copyright © 2006 Hindawi Publishing Corporation and the authors. 2006
Copyright_xml – notice: Copyright © 2006 Hindawi Publishing Corporation and the authors. 2006
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
8FD
FR3
P64
RC3
7X8
5PM
DOA
DOI 10.1155/2006/949506
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Engineering Research Database
Technology Research Database
Nucleic Acids Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
CrossRef
Genetics Abstracts
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 2210-7185
1875-8606
EndPage 272
ExternalDocumentID oai_doaj_org_article_f2e5e496853c4ee4bc4c055de4ccc494
10_1155_2006_949506
17167179
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID .GJ
0VX
29B
36B
4.4
53G
5GY
AAFWJ
AAJEY
ABDBF
ACGFS
ACPQW
ADBBV
ADRAZ
ADZMO
AFPKN
AFRHK
AGIAB
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
CAG
CGR
COF
CUY
CVF
DU5
DX2
EAD
EAP
EBS
ECM
EIF
EJD
EMB
EMK
EMOBN
EN4
EPL
ESX
F5P
GROUPED_DOAJ
HYE
IL9
IOS
IPNFZ
KQ8
M48
MIO
MV1
NGNOM
NPM
O9I
OK1
PGMZT
RIG
RPM
S1Z
S27
SV3
T13
TUS
WK8
---
0R~
24P
5VS
AAYXX
AENEX
BAWUL
CITATION
DIK
EBD
H13
HZ~
IAO
IHR
ITC
MET
O9-
RHX
7TM
8FD
FR3
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c476t-cff54b9888f6d0211058baed495d22609c66f7e1aee2df348ec7074d26ebcc463
IEDL.DBID RPM
ISSN 1570-5870
2210-7177
IngestDate Mon Nov 04 19:57:29 EST 2024
Tue Sep 17 20:37:12 EDT 2024
Fri Aug 16 07:06:53 EDT 2024
Fri Aug 16 22:15:37 EDT 2024
Fri Nov 22 02:45:53 EST 2024
Sat Sep 28 07:55:01 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5-6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c476t-cff54b9888f6d0211058baed495d22609c66f7e1aee2df348ec7074d26ebcc463
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618201/
PMID 17167179
PQID 20241639
PQPubID 23462
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_f2e5e496853c4ee4bc4c055de4ccc494
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4618201
proquest_miscellaneous_68247576
proquest_miscellaneous_20241639
crossref_primary_10_1155_2006_949506
pubmed_primary_17167179
PublicationCentury 2000
PublicationDate 2006-00-00
2006-01-00
20060101
2006-01-01
PublicationDateYYYYMMDD 2006-01-01
PublicationDate_xml – year: 2006
  text: 2006-00-00
PublicationDecade 2000
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Analytical cellular pathology (Amsterdam)
PublicationTitleAlternate Cell Oncol
PublicationYear 2006
Publisher IOS Press
Hindawi Limited
Publisher_xml – name: IOS Press
– name: Hindawi Limited
SSID ssj0032410
ssj0000399905
Score 2.1162603
Snippet Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and validate novel...
Background : Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and...
Background: Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and...
BACKGROUNDGene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and...
Background : Gene silencing through CpG island hypermethylation is a major mechanism in cancer development. In the present study, we aimed to identify and...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 259
SubjectTerms ADAM Proteins - genetics
ADAMTS1 Protein
Cell Line, Tumor
Colorectal Neoplasms - genetics
CpG Islands - genetics
DNA Methylation
Epigenesis, Genetic
Gene Expression Regulation, Neoplastic
Genes, Neoplasm
Humans
Microarray Analysis
Other
Promoter Regions, Genetic - genetics
Receptors, Glucocorticoid - genetics
Receptors, Retinoic Acid - genetics
Sequence Analysis, DNA
Tumor Cells, Cultured
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYKB9QL4tV2KaU-cCTaPPw8LruLuIAq2Eq9RX6MxUptFhH2wL_vOM4CW4F64RQpdhR7PsczX2x_Q8hJoQD9HDOZRe-ZMWdlpg3YzOpQKVtoLrtzaxc38uqXmkyjTM5Tqq-4JyzJAyfDDUMJHJgW6FYcA2DWMZdz7oE555hOSqC5WJGpNAdjlJB0CLjMM45Dsj-Zh85zGDn0UCMviEmOXviiTrL_tTjz3-2SL_zP-Q7Z7gNHOkoN3iUfoNkjW5f90vg-gdFkdDm7KU7p-Hp09gOvpvH06roaFzSdxg0YbVLT0uldVOBMhxd_P9IJ3Kd89FgaRahbOm_oGOfEOBfiG2fLPzF7ViyZtwfk5_l0Nr7I-hwKmWNSPGQuBM6sRp4bhM8j2-PKGvDYf4-RV66dEEFCYQBKHyqmwEmMKnwpwKJ9RfWJbDaLBr4QWlYyN1IZwzzCi06OKUTZGY_g-DyoATlZWbO-S1IZdUcxOI_JLkWdjD4gZ9HST1WivnV3A1Gve9Tr_6E-IN9XONX4PcRFDtPAYtnim8oYY-q3awhVMok0a0A-J1yfW4vkEektPivXEF9r63pJM7_tNLmZiEr4xeF7dO4r-fj8o-eIbD7cL-Eb2Wj98rgb5X8BuIv_eA
  priority: 102
  providerName: Directory of Open Access Journals
Title ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
URI https://www.ncbi.nlm.nih.gov/pubmed/17167179
https://search.proquest.com/docview/20241639
https://search.proquest.com/docview/68247576
https://pubmed.ncbi.nlm.nih.gov/PMC4618201
https://doaj.org/article/f2e5e496853c4ee4bc4c055de4ccc494
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6RHhAXRMvLtIQ99Ijr1z6PqZOqCKWq2iBxs_ZliNQ4Udwc-PedXduUIHrhZMnrx2pnvPN9651vEDrNhIM4R1SsIXrGxGgeS-V0rGVdCJ1JykPe2uUtv_oupjMvk0OHXJiwad_o5Vlztzprlj_D3srNyiTDPrHkel4S5mXHs2SERoANB4reTb8AEDoJAsrTmII39kl5EDcTT58TCZQgDZWLgCoAmZF7ESkI9_8Lbf69afKPKHTxCr3s4SOedN08RM9cc4Sez_sf5K-Rm0wn88Vt9hmXN5PzaziqxuKrm6LMcJeTWwPmxKrFs43X4exSGO9-4anbdlXpodVLUbd42eASZkY_I8IbF7uVr6HlW5btG_TtYrYoL-O-kkJsCGf3salrSrQEtlszm3rOR4VWzsJQWMBfqTSM1dxlyrnc1gURznDAFjZnThtDWPEWHTTrxr1HOC94qrhQilgwMoQ6IsDWRlnJhE1rEaHTYTSrTSeYUQWiQakvecmqbvwjdO5H-vclXuU6nFhvf1S9ras6d9QReDAtDHGOaENMSql1xECvJInQp8FOFXwV_leHatx618Kbco805dNXMJETDmQrQu86uz72tveLCPE9i-_1db8FHDUoc_eO-eG_7zxGLx7XeE7Qwf125z6iUWt3Y8D7X76Ow5rBOHj8A5DbAPg
link.rule.ids 230,315,729,782,786,866,887,2106,4028,27932,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWaFGh76b6oW3jIsYooievRkR24aGwEiQv0JnBTayCWDSs-9O871NLURXvJSYBIiRQ55MwTZ94gdJxKD3qO6tiA9oypNSJW2pvYqCqXJlVMtHFr0ysx_ybHk0CTw4ZYmNZp35rlSX29OqmXP1rfys3KJoOfWHIxKygPtONpcoDuw3olZADp3QYMJkJHQsAEiRnIYx-WB5ozCQA6UQAKSJu7CMACwBm1p5Na6v5_2Zt_u03-oYfOntzxC56ix73hiUdd8TN0z9fP0YNZf7T-AvnReDRbXKWfcHE5Or2Aq64dnl_mRYq7aN4KrFWsGzzZBAbPLvjx-ice-22Xzx5KA4l1g5c1LmBPDXsptLjYrUL2rVCybF6ir2eTRTGN-xwMsaWC38S2qhg1CnByxR0JaJFJo72DIXRguRFlOa-ET7X3matyKr0VYJW4jHtjLeX5K3RYr2v_BuEsF0QLqTV1IB6gJKkEKbHaKS4dqWSEjodZKDcd1UbZQhTGQrJMXnbzFqHTMEO_qwR-7PbGevu97Me4rDLPPIUXs9xS76mx1BLGnKcWeqVohI6G-S1hPYVDEl379a6BlrJgo6r_1-AyowJgWoRed_Jw29teniIk9iRlr6_7JSAgLad3LxBv7_zkEXo4XczOy_PP8y_v0KPbP0Xv0eHNduc_oIPG7T62K-UXDG8UiA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbtswECWaFAh66b4oXcJDjlW0cT06so0UrQ0jcYHeBK6tgVg2rPjQv89QkpO6aC_tSYBIiRQ55MwTZ94gdJoJB3qOqFiD9oyJ0TyWyulYS18InUnK27i1iys-_SaGo0CTc5fqq3XaN3pxVl8vz-rFj9a3cr00yc5PLJlNSsIC7XiWrK1PDtBDWLNpvgPq3SYMZkJHREB5GlOQyT40D7RnEkB0IgEYpG3-IgAMAGnknl5q6fv_ZHP-7jr5iy4aP_mPr3iKHvcGKB50VZ6hB65-jo4m_RH7C-QGw8FkfpV9xOXl4HwGV1VbPL0sygx3Ub0erFasGjxaBybPLgjy-iceuk2X1x5KA5l1gxc1LmFvDXsqtDjfLkMWrlCyaF6ir-PRvLyI-1wMsSGc3cTGe0q0BLzsmU0DaqRCK2dhGC1YcKk0jHnuMuVcbn1BhDMcrBObM6eNIax4hQ7rVe3eIJwXPFVcKEUsiAkoSyJAWoyykgmbehGh091MVOuOcqNqoQqlIWkmq7q5i9B5mKW7KoEnu72x2nyv-nGufO6oI_BiWhjiHNGGmJRS64iBXkkSoZPdHFewrsJhiardattAS3mwVeXfazCREw5wLUKvO5m4720vUxHie9Ky19f9EhCSltu7F4rjf37yBB3NhuPqy6fp57fo0f0Po3fo8Gazde_RQWO3H9rFcgvRPxcI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ADAMTS1%2C+CRABP1%2C+and+NR3C1+identified+as+epigenetically+deregulated+genes+in+colorectal+tumorigenesis&rft.jtitle=Cellular+oncology+%3A+the+official+journal+of+the+International+Society+for+Cellular+Oncology&rft.au=Lind%2C+Guro+E&rft.au=Kleivi%2C+Kristine&rft.au=Meling%2C+Gunn+I&rft.au=Teixeira%2C+Manuel+R&rft.date=2006&rft.issn=1570-5870&rft.volume=28&rft.issue=5-6&rft.spage=259&rft_id=info:doi/10.1155%2F2006%2F949506&rft_id=info%3Apmid%2F17167179&rft.externalDocID=17167179
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1570-5870&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1570-5870&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1570-5870&client=summon